This Phase 1 study found that a monoclonal antibody to Grp78 (PAT-SM6) was well tolerated and was associated with 33.3% stable disease in relapsed or refractory multiple myeloma [112]. This evidence concerns the gene HSPA5 and plasma cell myeloma.